Subcutaneous infliximab biosimilar for treating inflammatory conditions

Published on 13 Sep 2024
Last Updated on 13 Sep 2024

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has not recommended subcutaneous infliximab biosimilar (Remsima) for inclusion on the MOH List of Subsidised Drugs for treating rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, Crohn’s disease, and ulcerative colitis. The decision was based on unacceptable pricing proposal from the company.

Subcutaneous infliximab biosimilar for treating inflammatory conditions (Published 13 Sep 2024) [PDF, 89 KB]